References
- Cosman F, Lindsey R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20:418–34
- Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe LP Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:212–24
- Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ER-a and ER-I3 at API sites. Science 1997;277: 1508–10
- Cano A, Hermenegildo C. Modulation of the oestrogen receptor: a process with distinct susceptible steps. Hum Reprod Update 2000; 6:207–11
- Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
- Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene — results from a 3-year random-ized clinical trial. J Am Med Assoc 1999;282: 637–45
- Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women — results from the MORE randomized trial. J Am Med Assoc 1999;281:2189–97
- Azevedo GD, Prado MFM, Ferriani RA, et al. Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study. Maturitas 2003;in press
- Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998;279:1445–51
- De Valk-de-Roo GW, Stehouwer CD, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy post-menopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999;19: 2993–3000
- Dahlbäck B. Blood coagulation. Lancet 2000; 355:1627–32
- Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol 1996; 7:671–5
- Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996;156: 1806–10
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88
- Herrington DM, Pusser BE, Riley WA, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2000;20:1606–12
- Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post-menopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17:3071–8
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progesterone for secondary prevention of coronary artery disease in postmenopausal women. Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605–13
- Koh KK, Horne MK, Cannon RO. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmeno-pausal women. Thromb Haemost 1999;82: 626–33
- Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemo-static variables in women with previous venous thromboembolism — results from a randomized, double-blind, clinical trial. Tbromb Haemost 2001;85:775–81
- Mammen EF. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982;142:781–90
- Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJT. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10–19